Several studies suggested that IL‐33 could be considered as a tumour biomarker; IL‐33/ST2 signalling have a pro‐tumourigenic role in head and neck squamous cancer, breast cancer, non‐small‐cell lung cancer, cholangiocarcinoma, gastric cancer and myeloproliferative neoplasm. Here, IL33 is linked to myeloproliferative disorder.